Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2737373 | 1.00 | HRH3 (0.42) | HRH3KCNH2LIPEGBA1BRD4 | |
| SCHEMBL2737426 | 1.00 | HRH3 (0.42) | HRH3KCNH2LIPEGBA1BRD4 | |
| SCHEMBL10017898 | 0.88 | LIPE (0.39) | HRH3KCNH2LIPE | |
| SCHEMBL10017897 | 0.88 | LIPE (0.39) | HRH3KCNH2LIPE | |
| SCHEMBL1789883 | 0.88 | LIPE (0.39) | HRH3KCNH2LIPE | |
| SCHEMBL2943697 | 0.86 | HRH3 (0.51) | HRH3KCNH2 | |
| SCHEMBL25124984 | 0.86 | LIPE (0.35) | HRH3KCNH2LIPEGBA1 | |
| SCHEMBL19730657 | 0.83 | HRH3 (0.38) | HRH3KCNH2BRD4 | |
| SCHEMBL17776661 | 0.83 | HRH3 (0.38) | HRH3KCNH2BRD4 | |
| SCHEMBL26703137 | 0.83 | HRH3 (0.38) | HRH3KCNH2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148005-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | THESEUS PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230148005-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | THESEUS PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20220213065-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| US-11247965-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2021252678-A1 | HETEROARYL ALKYLENE SUBSTITUTED 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210171439-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020198526-A2 | SMALL MOLECULE MODULATORS OF PANK | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2020-10-01 | — | — | WO | disclosed |
| US-10669262-B2 | Aminopyrazine diol compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190276435-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2019-09-12 | — | — | US | disclosed |
| US-20190263799-A1 | 1H-IMIDAZO[4,5-B]PYRIDINYL AND 2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDINYL HETEROCYCLIC BET BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2019-08-29 | — | — | US | disclosed |
| WO-2019118358-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2019-06-20 | — | — | WO | disclosed |
| US-9365583-B2 | Substituted pyrazoles and uses thereof | GENENTECH, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150175619-A1 | SUBSTITUTED PYRAZOLES AND USES THEREOF | GENENTECH, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-8188272-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100105676-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148005-A1 | MACROCYCLIC COMPOUNDS AND USES THEREOF | EGFR, ERBB2, ERBB3 | HRH3 4374/4885KCNH2 3492/4885LIPE 4589/4885 |
| US-10669262-B2 | Aminopyrazine diol compounds as PI3K-γ inhibitors | PIK3CD, PIK3R5, PIK3CG | HRH3 2516/4885KCNH2 1238/4885LIPE 3861/4885 |
| US-20100105676-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BTK, LYN, ABL1 | HRH3 1790/4885KCNH2 1162/4885LIPE 4081/4885 |
| US-20150175619-A1 | SUBSTITUTED PYRAZOLES AND USES THEREOF | PDXK, NLK, PDK3 | HRH3 1407/4885KCNH2 1891/4885LIPE 3792/4885 |
| US-20190276435-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | PIK3CD, PIK3R5, PIK3CG | HRH3 2830/4885KCNH2 1077/4885LIPE 3878/4885 |
| US-20210171439-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | HRH3 4079/4885KCNH2 4785/4885LIPE 4214/4885 |
| US-20220213065-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | PIK3CD, PIK3R5, PIK3CG | HRH3 2830/4885KCNH2 1077/4885LIPE 3878/4885 |
| US-11247965-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | HRH3 4079/4885KCNH2 4785/4885LIPE 4214/4885 |
| US-20190263799-A1 | 1H-IMIDAZO[4,5-B]PYRIDINYL AND 2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDINYL HETEROCYCLIC BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | HRH3 661/4885KCNH2 2399/4885LIPE 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.